Antidepressant Works in Treating Painful Neuropathy

Patients who experience chemotherapy-induced peripheral neuropathy may find relief with the antidepressant Cymbalta.

Patients who experience chemotherapy-induced peripheral neuropathy (CIPN), an often painful side effect that can involve numbness and tingling in the hands and feet, may find relief with the antidepressant Cymbalta (duloxetine), according to results from a phase 3 study. Although currently approved for the treatment of diabetic peripheral neuropathic pain, Cymbalta is the first drug that has proven effective in treating CIPN.

Experienced by about one-third of patients treated with taxanes and platinum-based chemotherapy, CIPN can develop weeks, months or years after treatment. Symptoms generally resolve completely, although healing of damaged nerves can take a few weeks to many months or even years.

In the study, 231 patients who had previously reported high levels of pain from CIPN were randomized to one of two arms. Participants in Arm A received Cymbalta for five weeks. After a one-week “washout” period, they received a placebo for five weeks. Participants in Arm B did the opposite, beginning with a placebo and ending with Cymbalta. Researchers reported a statistically significant decrease in pain for those taking Cymbalta in the initial treatment period. The most common side effect was fatigue.

Unfortunately, the drug didn’t work for everyone, which presents the next challenge, says lead investigator Ellen Lavoie Smith, PhD, APRN, AOCN, of the University of Michigan School of Nursing. “We’ll try to identify who will respond so we can target this drug to those who are most likely to benefit.”

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol